Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica.
Lipopolysaccharide Upregulates the Expression of CINC-3 and LIX in Primary NG2 Cells.
Biologically plausible and evidence-based risk intervals in immunization safety research.
Enhanced In Vivo Efficacy of a Type I Interferon Superagonist with Extended Plasma Half-life in a Mouse Model of Multiple Sclerosis.
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
Natalizumab treatment of progressive multiple sclerosis (NAPMS)
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Effects of early IL-17A neutralization on disease induction in a primate model of experimental autoimmune encephalomyelitis.
Microglia: Architects of the Developing Nervous System.
Prolongation of survival of rat cardiac allografts by T cell vaccination.
Simvastatin inhibits interferon-gamma-induced MHC class II up-regulation in cultured astrocytes.
Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations.
Expression of Ccl11 Associates with Immune Response Modulation and Protection against Neuroinflammation in Rats.
Use of Complementary and Alternative Medicine among People with Multiple Sclerosis in the Nordic Countries.
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis.
Neuroprotection in Huntington's disease: a 2-year study on minocycline.
A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients.
Haplotypes across the human caveolin 1 gene upstream purine complex significantly alter gene expression: Implication in neurodegenerative disorders.
Extracting quantitative measures from EAP: a small clinical study using BFOR.
Low dose naltrexone therapy in multiple sclerosis.
Signaling and Regulatory Functions of Bioactive Sphingolipids as Therapeutic Targets in Multiple Sclerosis.
Interleukin-2 and the brain: dissecting central versus peripheral contributions using unique mouse models.
Perforin Expression by CD4+ Regulatory T Cells Increases at Multiple Sclerosis Relapse: Sex Differences.
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.

Pages